Published in Health Business Week, February 9th, 2007
The second closing will occur within 120 days from the date of the first closing, bringing the total series A round to $12 million.
The funds will enable the company to advance its lead vaccine products for influenza and pneumonia indications to clinical trials. The company will also pursue immunotherapy products for hepatitis B and biodefense applications. The funds permitted the company to close asset purchase agreements negotiated with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.